07 December 2023 : Clinical Research
Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study
Beata Kotowicz
1ACDEF*, Anna Dańska-Bidzińska 2ABDEG, Małgorzata Fuksiewicz 1BCDE, Anna Nasierowska-Guttmejer 3BC, Dorota Raczkiewicz 4C, Mariusz Gujski 5BEF, Szymon Piątek 6B, Mariusz Bidziński 6AEG
DOI: 10.12659/MSM.941562
Med Sci Monit 2023; 29:e941562
Table 1 Patients’ characteristics.
| Variable, parameter | Unit or category | Number of patients (%) (n=52) |
|---|---|---|
| Age of onset, min-max, median | Years | 56 (23–93) |
| Age group | <60 years | 32 (62) |
| ≥60 years | 20 (38) | |
| FIGO stage | IA | 11 (21) |
| IB | 24 (46) | |
| IIA | 12 (23) | |
| IIB | 4 (8) | |
| IIIA | 1 (2) | |
| Type of tumor | Primary | 38 (73) |
| Recurrent | 14 (27) | |
| Histology type | Carcinosarcoma | 18 (35) |
| Leiomyosarcoma | 13 (25) | |
| ESS high grade* | 10 (19) | |
| Adenosarcoma | 5 (10) | |
| ESS low grade* | 4 (8) | |
| Rhabdomyosarcoma | 1 (2) | |
| Solitary fibrous tumor (malignant) | 1 (2) | |
| Type of adjuvant treatment | Chemotherapy | 24 (46) |
| Radiotherapy | 8 (16) | |
| Hormonal treatment | 9 (17) | |
| No treatment | 11 (21) | |
| Mitotic index Ki 67 | Low | 12 (23) |
| Medium | 8 (15) | |
| High | 32 (62) | |
| p53 | Low | 11 (21) |
| High | 41 (79) | |
| Estrogen receptors status | Low | 37 (71) |
| High | 15 (29) | |
| Progesterone receptors status | Low | 43 (83) |
| High | 9 (17) | |
| * ESS – endometrial stromal sarcoma. | ||